Nova Mentis Life Science Corp. announced that the Company has formed a tactical partnership with KGK Science Inc. to develop its psychedelic psilocybin drug portfolio in Canada. KGK is a leading North American contract research organization based in London, Ontario that primarily provides high-quality clinical research trials with a focus on the nutraceutical, cannabis and emerging psychedelic industries.

Both Companies plan to jointly submit a clinical trial application ("CTA") to Health Canada for a Phase 2A clinical study evaluating psilocybin microdose therapy for fragile X syndrome.